This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Will USTR's 25% Tariff Exemption Spell Relief for MedTech?
by Urmimala Biswas
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.
Earnings Preview: Boston Scientific (BSX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US-India Trade Tensions Rise: 3 Stocks in the Line of Fire
by Sreyoshi Mukherjee
As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.
Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD
by Urmimala Biswas
The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.
The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
Boston Scientific's Global Growth Robust Amid Currency Woe
by Zacks Equity Research
Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.
Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Eli Lilly (LLY) and Boston Scientific (BSX).
Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout
by Zacks Equity Research
The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.
Edwards Lifesciences Recalls Heart Device on Balloon Rupture
by Zacks Equity Research
Shares of Edwards Lifesciences (EW) decline post product recall news.
Stock Market News for Jul 3, 2019
by Zacks Equity Research
Wall Street registered decent gains on Tuesday.
Varian to Acquire Boston Scientific's Embolic Bead Products
by Zacks Equity Research
Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.
Boston Scientific Strong on Growth Goals and Future Launches
by Zacks Equity Research
This long-range strategy will aid Boston Scientific (BSX) to deliver a solid financial footing across its MedSurg, Rhythm and Neuro plus Cardiovascular segments.
CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?
by Urmimala Biswas
While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.
Near-Term Outlook for Medical Instruments Industry Bleak
by Urmimala Biswas
Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.
Boston Scientific's New Products, Acquisitions Boost Growth
by Zacks Equity Research
Boston Scientific (BSX) is pulling out all the stops to strengthen its core businesses as well as invest in new technologies and the overseas markets.
Boston Scientific (BSX) Announces Vertiflex Acquisition
by Zacks Equity Research
The acquisition is in sync with Boston Scientific's (BSX) strategy of expanding pain management portfolio.
Top Stock Reports for Johnson & Johnson, Chevron & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Chevron (CVX) and Adobe (ADBE).
VREX or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
VREX vs. BSX: Which Stock Is the Better Value Option?
Why Is Boston Scientific (BSX) Up 2.3% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News For Apr 25, 2019
by Zacks Equity Research
Companies In The News Are: DPZ, BSX, TXN, BA
Boston Scientific (BSX) Misses Q1 Earnings, Tightens EPS View
by Zacks Equity Research
Boston Scientific (BSX) is investing in new technologies and the global markets, which in turn, aids the uptick in sales across its most geographies in Q1.
Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?
by Zacks Equity Research
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Boston Scientific (BSX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott's (ABT) HeartMate 3 Pump Study Shows Favorable Results
by Zacks Equity Research
The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.